ABOUT
Company Profile
CALGENT, a spin-off company of Taipei Medical University (TMU), was established in 2019 and thrives on applying science and technology to drug development. We are committed to developing innovative drugs for novel therapeutic cancer targets and various treatments for inflammatory and immune system related diseases.
Consists of talented experts who have forged decades worth of strong biotech and clinical connections and experiences. CALGENT is operated by a lean R&D operational team in Taiwan and a senior scientific team located overseas. We can effectively to develop exceptional and innovative medicines with the potential to bring positive and profound impacts on improving the life quality for patients with unmet needs.
CALGENT has years of experience in pharmaceutical development and rich resources from university-industry research collaboration, combined with the molecular simulation, preclinical screening strategies and clinical research database, CALGENT has demonstrated the great ability to execute a complete potential drug targets development.
Besides the development of new drugs as the core technologies, CALGENT has also established the clinical trial and precision medical platform partnerships to expand R&D and innovation abilities, enhance the efficiency of resources utilization, and create an integrity of the value chain at biopharmaceutical industry.
Business Strategies
Committed to provide competitive products and services to meet unmet medical needs
Focused on the development of novel oncology drugs, anti-inflammatory drugs and other drugs.
Creating value-added strategies for clinical research to improve the value of new drugs development
With extensive experience in designing clinical trial and regulatory strategies to increase the successful rate on clinical trials and value of new drug development.
Establishing a comprehensive drug development capability from non-clinical to clinical stage and effective international collaboration
Use the rich resources from university-industry research collaboration to introduce the potential lead compounds and/or drug targets in clinical phase I locally and internationally. Improved the efficiency and success rate of drug development through drugs structure modification and optimization strategies.
Using goal orientation thinking and project management model for improving the efficiency of new drug development
Based on the target product profile and strategies in drug development, project managers can execute their projects more efficiently through the systematic management and resource coordination to manage the vendors/CROs/CMOs for accelerating new drug development times.
Management Team
Chair of Board
Dr. Yun Yen MD, PhD
Education
- Taipei Med University (MD)
- Thomas Jefferson University (PhD)
- Yale University School of Medicine (Hem Onc Fellow)
Career Experience
- 40+ years in Oncology, Cancer Therapeutics, Translational Medicine, Cancer Genomics, Academia, Philanthropy
- 80+ patents (commercialized methodologies in nanoparticles, small/large molec drugs, biomarkers, stem cells, and medical devices)
- 400+ peer reviewed publications
- Taipei Medical University (President)、City of Hope (Endowed Chair in Develop Cancer Therapeutics、Chair Molecular Pharmacology and Medical Oncology、Associate Cancer Center Director Translational Research)、Affiliate Professor of Caltech、Case Western Reserve University、Chair Professor Taipei Medical University、National Academy of Inventors、AAAS Fellow
- Business：Pharmaceutical (Co-Founder, Board, US public) 、Lixte Biopharma (Board, US public) 、Tanvex Biopharma (Chair of Board, Taiwan public) 、OBI Pharma (Board, Taiwan public)
CEO
Hui Wen Huang, EMBA
CEO Huang received the EMBA degree from the Department and Graduate Institute of Business Administration at the National Taiwan University. She has 10 years of sales-marketing experience, 16 years of intellectual property management, regulatory strategy development , innovation coaching and business development experience in the biomedical sector. She was also involved in government consultation and being a reviewer with a deep focus on intellectual property management, creativity, innovation coaching and new policies development.
CSO
Ya Wen Cheng, PhD
Dr. Cheng was graduated from the Institute of Medicine at the Chung Shan Medical University. She was formerly the Director & Professor, PhD Program of Cancer Biology and Drug Discovery, Taipei Medical University; Professor, Institute of Medicine, Chung Shan Medical University. She has over 25 years of R/D experience in toxicology, cancer biology, viral oncology, and translational Medicine; with expertise in DMPK, PD, and drug candidate selection.
Senior Manager of Business Dept.
Alice Yang, EMBA
Alice Yang specializes in Regulatory affairs, Project management, Market and Industry analysis and Legal affairs management. She is a PhD candidate of School of Business, Chang Gung University, Taiwan. And she received her 3 master degrees from Professional Master’s Program of Law in Business Administration at National Taiwan University, School of Business at Chang Gung University and the Medical Institute at Kaohsiung Medical University. She has worked at Lotus Pharmaceutical Co.,LTD., Synpac-Kingdom Pharmaceutical Co.,Ltd. and TFDA. She has more than 16 years of experience in regulatory affairs and project management.
Senior Manager of Finance Dept.
Ya Ching Yu
Sunny Yu received the master of Public Health Degree Program (Health Services Administration Field) from National Taiwan University. She has more than 26 years of experience in accounting, finance, audit and project management field. She previously worked at research new drug biotech company, generic drug pharmaceutical company, healthcare management company, high technology company and investment bank.
CEO
Hui Wen Huang, EMBA
CEO Huang received the EMBA degree from the Department and Graduate Institute of Business Administration at the National Taiwan University. She has 10 years of sales-marketing experience, 16 years of intellectual property management, regulatory strategy development , innovation coaching and business development experience in the biomedical sector. She was also involved in government consultation and being a reviewer with a deep focus on intellectual property management, creativity, innovation coaching and new policies development.
Director of CMC Dept.
Yu-Tsai Yang, Ph.D.
Dr. Yang graduated from the Taipei Medical University. He was formerly the R&D Director, INNOPHARMAX, Inc. Post-doctoral Fellow, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA. Post-doctoral Fellow, Department of Biochemical Science and Technology, National Taiwan University, Taipei. He was a pharmaceutical scientist with over 15 years of successful experience in formulations and process development. Experience in developing an oral delivery platform for protein drugs, granted multi-national patent.
Senior Manager of Business Dept.
Alice Yang, EMBA
Alice Yang specializes in Regulatory affairs, Project management, Market and Industry analysis and Legal affairs management. She is a PhD candidate of School of Business, Chang Gung University, Taiwan. And she received her 3 master degrees from Professional Master’s Program of Law in Business Administration at National Taiwan University, School of Business at Chang Gung University and the Medical Institute at Kaohsiung Medical University. She has worked at Lotus Pharmaceutical Co.,LTD., Synpac-Kingdom Pharmaceutical Co.,Ltd. and TFDA. She has more than 16 years of experience in regulatory affairs and project management.
Chief Financial Officer of Finance Dept.
Sherry Dai, MBA
Sherry received the master degree of MBA, from National Taipei University. She has worked in semiconductor companies, high-tech companies, medical materials companies, and monocrystalline silicon solar cell companies. More than 25 years of experience as a professional manager in accounting, finance, auditing and management fields.
Scientific Advisory Board
Robert B. Diasio, M.D.
Mayo Clinic Cancer Center
James Mulé, PhD
Moffitt Cancer Center
Jacqueline Whang-Peng, M.D., Ph.D.
Academician, Academia Sinica, ROC
Robert B. Diasio, M.D.
Mayo Clinic Cancer Center
James Mulé, PhD
Moffitt Cancer Center
Jacqueline Whang-Peng, M.D., Ph.D.
Academician, Academia Sinica, ROC